Literature DB >> 16633

Measurement of thioridazine in blood and urine.

C H Ng, J L Crammer.   

Abstract

1 Thioridazine can be specifically, simply, and reliably measured in plasma and urine by gas chromatography using hexane extraction and prochlorperazine as internal standard; fluorimetry is non-specific. 2 The method can also measure thioridazine ring sulphoxide, and mesoridazine-plus-sulphoridazine (M/S). 3 After single doses plasma sometimes shows M/S in addition to thioridazine itself; it always does so on continued treatment. There is great individual variation in both components, and evidence of changes in metabolism during the early weeks. 4 Urinary excretion may be influenced by pH, but between pH 6.0-7.0 about 1% of the daily dose appears in 24 h urine as the following: free thioridazine in microng quantities, M/S and ring sulphoxide each in mg amounts. 5 Patients attain steady state conditions, although plasma levels rise considerably after each dose and settle again in about 10 h. After chronic treatment is stopped to half-life is at about 30 h. 6 Plasma levels cannot be related to therapeutic response when this is slow, as in schizophrenia, but interpretations are complicated by the production of clinically active metabolites, and by plasma protein binding.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 16633      PMCID: PMC1429017          DOI: 10.1111/j.1365-2125.1977.tb00691.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  12 in total

1.  Plasma levels and clinical effects of thioridazine and thiothixene.

Authors:  R Bergling; T Mjorndal; L Oreland; W Rapp; S Wold
Journal:  J Clin Pharmacol       Date:  1975 Feb-Mar       Impact factor: 3.126

2.  Thioridazine plasma levels and clinical response.

Authors:  L A Gottschalk; R Biener; E P Noble; H Birch; D E Wilbert; J F Heiser
Journal:  Compr Psychiatry       Date:  1975 Jul-Aug       Impact factor: 3.735

3.  Albumin binding of thioridazine and some of its metabolites.

Authors:  F A Vandeheeren; F M Belpaire
Journal:  Arch Int Pharmacodyn Ther       Date:  1975-03

4.  THE EXCRETION AND METABOLISM OF 35S-LABELED THIORIDAZINE IN URINE, BLOOD, BILE, AND FECES.

Authors:  S EIDUSON; E GELLER
Journal:  Biochem Pharmacol       Date:  1963-12       Impact factor: 5.858

5.  Mesoridazine versus chlorpromazine in acute schizophrenia: a double-blind investigation.

Authors:  T A Hamid; W J Wertz
Journal:  Am J Psychiatry       Date:  1973-06       Impact factor: 18.112

6.  Therapeutic effect and plasma level of thioridazine.

Authors:  F E de Jonghe; H J van der Helm; H F Schalken; J H Thiel
Journal:  Acta Psychiatr Scand       Date:  1973       Impact factor: 6.392

7.  Gas chromatographic identification of thioridazine in plasma, and a method for routine assay of the drug.

Authors:  S H Curry; G P Mould
Journal:  J Pharm Pharmacol       Date:  1969-10       Impact factor: 3.765

8.  Theoretical changes in drug distribution resulting from changes in binding to plasma proteins and to tissues.

Authors:  S H Curry
Journal:  J Pharm Pharmacol       Date:  1970-10       Impact factor: 3.765

9.  Serum levels of thioridazine in psychiatric patients and healthy volunteers.

Authors:  E Mårtensson; B E Roos
Journal:  Eur J Clin Pharmacol       Date:  1973-10       Impact factor: 2.953

10.  Plasma concentrations of thioridazine in patients with depression. A preliminary report.

Authors:  F E de Jonghe; J H van der Helm
Journal:  Acta Psychiatr Scand       Date:  1970       Impact factor: 6.392

View more
  5 in total

Review 1.  Plasma level monitoring of antipsychotic drugs.

Authors:  T B Cooper
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

2.  A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia.

Authors:  Lili Aslostovar; Allison L Boyd; Mohammed Almakadi; Tony J Collins; Darryl P Leong; Rommel G Tirona; Richard B Kim; Jim A Julian; Anargyros Xenocostas; Brian Leber; Mark N Levine; Ronan Foley; Mickie Bhatia
Journal:  Blood Adv       Date:  2018-08-14

3.  Red blood cell and plasma levels of thioridazine and mesoridazine in schizophrenic patients.

Authors:  A Shvartsburd; V Nwokeafor; R C Smith
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

4.  The biotransformation of thioridazine to thioridazine 5-sulfoxide stereoisomers in phenobarbital induced rats.

Authors:  P W Hale; A Poklis
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1986 Oct-Dec       Impact factor: 2.441

5.  Fluoxetine and thioridazine inhibit efflux and attenuate crystalline biofilm formation by Proteus mirabilis.

Authors:  Jonathan Nzakizwanayo; Paola Scavone; Shirin Jamshidi; Joseph A Hawthorne; Harriet Pelling; Cinzia Dedi; Jonathan P Salvage; Charlotte K Hind; Fergus M Guppy; Lara M Barnes; Bhavik A Patel; Khondaker M Rahman; Mark J Sutton; Brian V Jones
Journal:  Sci Rep       Date:  2017-09-22       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.